¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"progressive resistance exercise"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • airway resistance
    ±âµµÀúÇ×
  • bladder outlet resistance
    ¹æ±¤ÃⱸÀúÇ×
  • coronary vascular resistance
    °ü»óÇ÷°üÀúÇ×, ½ÉÀåÇ÷°üÀúÇ×
  • cross-resistance
    ±³Â÷ÀúÇ×
  • cerebral vascular resistance
    ³úÇ÷°üÀúÇ×
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
  • electric skin resistance
    ÇǺÎÀü±âÀúÇ×
  • flow resistance
    È帧ÀúÇ×, À¯·®ÀúÇ×
  • frictional resistance
    ¸¶ÂûÀúÇ×
  • genetic resistance
    À¯ÀüÀúÇ×
  • heterogeneous resistance
    ºñ±ÕÀÏÀúÇ×
  • insulation resistance
    Àý¿¬ÀúÇ×
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • cross-resistance
    ±³Â÷ÀúÇ×
  • cerebral vascular resistance
    ³úÇ÷°üÀúÇ×
  • coronary vascular resistance
    ½ÉÀåÇ÷°üÀúÇ×, °ü»óÇ÷°üÀúÇ×
  • cross resistance
    ±³Â÷³»¼º
  • resistance coil
    ÀúÇ×ÄÚÀÏ
  • donor resistance
    ÁÖ´ÂÀÌÀúÇ×¼º
  • drug resistance
    ¾à¹°³»¼º
  • drug resistance factor
    ¾àÁ¦ÀúÇ×ÀÎÀÚ
  • resistance donor
    ÀúÇ×¼ºÁ¦°øÃ¼, ÀúÇ×¼ºÁÖ°Ô
  • effective membrane resistance
    À¯È¿¸·ÀúÇ×
  • electric skin resistance
    ÇǺÎÀü±âÀúÇ×
  • flow resistance
    È帧ÀúÇ×, À¯·®ÀúÇ×
  • frictional resistance
    ¸¶ÂûÀúÇ×
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • resistance furnace
    ÀúÇ×·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • progressive myopia
    ÁøÇ༺ ±Ù½Ã(òäú¼àõ ÐÎãÊ) ¾Æµ¿ÀÇ
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(¡­ãêÌèàõÐÉê×õê).
  • progressive neural muscular atrophy
    ÁøÇ༺ ½Å°æ¼º ±ÙÀ§Ãà(òäú¼àõ ãêÌèàõ ÐÉê×õê)
  • progressive nodular fibrosis of the skin
    ÁøÇ༺ °áÀý ÇǺΠ¼¶À¯Áõ
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ.
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ ÇÙ¼º ¾È±Ù¸¶ºñ(òäú¼àõ ú·àõ äÑÐÉØ¦Ýö)
  • progressive nuclear ophthalmoplegia
    ÁøÇ༺ÇÙ¼º¾È±Ù¸¶ºñ
  • progressive ophtalmoplegia
    ÁøÇ༺ ¾È±Ù ¸¶ºñ(òäú¼àõ äÑÐÉØ¦Ýö)
  • progressive pigmentary dermatosis
    ÁøÇ༺ »ö¼Ò¼º ÇǺÎÁõ
  • progressive pigmentary dermatosis
    ÁøÇ༺ »ö¼Ò¼º ÇǺÎÁõ(òäú¼àõ ßäáÈàõ ù«Ý±ñø)
  • progressive spastic spinal paralysis
    ÁøÇ༺ °æ¼º ô¼ö¸¶ºñ(òäú¼àõÌâàõô±âÐ Ýö).
  • progressive spastic spinal paralysis
    ÁøÇ༺ °æ¼º ô¼ö¸¶ºñ(òäú¼àõ Ìâàõ ô±âÐØ¦Ýö)
  • progressive spinal amyotrophy
    ÁøÇ༺ ô¼ö¼º ±ÙÀ§ÃàÁõ(òäú¼àõô±âÐàõÐÉê×õê ñø).
  • progressive spinal amyotrophy
    ÁøÇ༺ ô¼ö¼º ±ÙÀ§ÃàÁõ(òäú¼àõ ô±âÐàõ ÐÉê×õêñø)
  • progressive subcortical encephalopathy
    ÁøÇ༺ ÇÇÁúÇϳúÀå¾Ö<³úÁõ>(¡­ù«òõù» Òàî¡äô<Òàñø>).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • hereditary progressive mucinous histiocytosis X
    À¯Àü¼º ÁøÇ༺ Á¡¾×¼ºÁ¶Á÷±¸Áõ
  • infantile progressive spinal muscular atrophy
    ¿µ¾ÆÁøÇ༺ ô¼ö¼º ±ÙÀ§Ãà(Áõ).
  • juvenile progressive muscular atrophy
    ¿¬¼Ò¼º ÁøÇ༺ ±ÙÀ§ÃàÁõ(¡­òäú¼àõÐÉê× õêñø).
  • keratosis extremitatum progrediens => progressive diffuse keratoderma
  • leukoencephalopathy,progressive multifocal
    º´Áõ(Ü»ñø)
  • malignant progressive histiocytoma
    ¾Ç¼º ÁøÇ༺ Á¶Á÷±¸Á¾
  • multiple progressive angioma
    ´Ù¹ß¼º ÁøÇ༺ Ç÷°üÁ¾
  • myopathic progressive muscular atrophy
    ±Ùº´Áõ¼º ÁøÇ༺ ±ÙÀ§Ãà(Áõ)(¡­òäú¼àõÐÉê×õêñø).
  • neural progressive muscular atrophy
    ½Å°æ¼º ÁøÇ༺ ±ÙÀ§Ãà(Áõ).
  • neural progressive muscular atrophy
    ½Å°æ¼º ÁøÇ༺ ±ÙÀ§Ãà(Áõ)(¡­òäú¼àõ ÐÉê×õêñø)
  • paralysis, progressive facial
    ÁøÇ༺ ¾È¸é¸¶ºñ
  • progressive
    ÁøÇ༺
  • progressive
    ÁøÇ༺ÀÇ(òäú¼àõ¡­), Á÷Áø(¼º)ÀÇ(òÁòä(àõ)¡­)
  • progressive bulbar palsy
    ÁøÇ༺ ±¸<¿¬¼ö>¸¶ºñ(òäú¼àõϹ<æÅâÐ> Ýö).
  • progressive cardiomyopathic lentiginosis
    ÁøÇ༺ ½É±Ùº´¼º ÈæÀÚÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
TPR temperature, pulse, and respiration; testosterone production rate; third party reimbursement; total ...
TPVR total peripheral vascular resistance; total pulmonary vascular resistance
PMF Progressive Massive Fibrosis
  = Silicosis
PRP   1) Progressive Rubella Panencephalitis
  2) Platelet Rich Plasma
 &...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ETT exercise treadmill test
SET standardised exercise test
CPEO Chronic Progressive External Ophthalmoplegia
OPP Ovine progressive pneumonia
PPA Primary Progressive Aphasia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • peripheral resistance unit
    ¸»ÃÊ ÀúÇ× ´ÜÀ§
  • platinum resistance furnace
    Àü±â ¼Ò¼º·Î, ¹é±Ý ·Î
  • radiation resistance
    ¹æ»ç¼± ÀúÇ×
  • resistance
    °ÅºÎ, ÀúÇ×, ÀúÇ×¼º, ³»¼º
    Àü·ù Åë°ú¿¡ ´ëÇÏ¿© µµÃ¼¿¡ ÀÇÇÑ ÀúÇ×. Á¤½Å ºÐ¼®¿¡ À־´Â ¾ï¾ÐµÈ °ÍÀÌ ÀǽÄÀ¸·Î µÇ´Â °Í¿¡ ´ëÇÑ ÀúÇ×. Á¤»óÀÇ »ý¹°ÀÌ È¯°æ³»ÀÇ µ¶¹°, ¿¹ÄÁµ¥ µ¶, µ¶¼Ò, Àڱع°, º´¿ø¼º ¹Ì»ý¹° µî¿¡ ´ëÇÏ¿© ÀÚ¿¬ÀûÀ¸·Î °®´Â ³»¼º.
  • resistance factor
    ³»¼º ÀÎÀÚ
  • resistance form of cavity
    ¿Íµ¿ÀÇ ÀúÇ× ÇüÅÂ
  • resistance reflex
    ÀúÇ× ¹Ý»ç
  • resistance to corrosion
    ³»½Ä¼º
  • sleep resistance
    Àá ÅõÁ¤
  • weather resistance
    ±âÈÄ ÀúÇ×¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
tetracycline resistance Nonsusceptibility of a microbe (usually a bacterium) to the action of tetracycline, which binds to the 30s ribosomal subunit and prevents the normal binding of aminoacyl-trna.
(12 Dec 1998)
thyroid hormone resistance syndrome <syndrome> An inherited syndrome of peripheral resistance to thyroid hormones, transmitted as an autosomal recessive trait, characterised by increased serum concentrations of thyroxine and triiodothyronine, increased thyroid hormone binding ratio, and normal to slightly increased thyroid-stimulating hormone and its response to thyrotropin-releasing hormone. The affected persons are euthyroid to slightly hypothyroid. The absence of hypermetabolism and the presence of possible hypothyroidism indicate the existence of partial resistance to the peripheral action of thyroid hormone.
(12 Dec 1998)
thyrotropin resistance An autosomal recessive disorder in which the thyrocytes are unresponsive to thyrotropin.
Compare: pseudohypoparathyroidism.
(05 Mar 2000)
total peripheral resistance The total resistance to flow of blood in the systemic circuit; the quotient produced by dividing the mean arterial pressure by the cardiac minute-volume.
Synonym: peripheral resistance.
(05 Mar 2000)
trimethoprim resistance Nonsusceptibility of a bacterium to the action of trimethoprim.
(12 Dec 1998)
expiratory resistance Resistance to flow of gas out of the lungs or the total resistance to flow of gas during the expiratory phase of the respiratory cycle.
(05 Mar 2000)
kanamycin resistance Nonsusceptibility of bacteria to the antibiotic kanamycin, which can bind to their 70s ribosomes and cause misreading of messenger RNA.
(12 Dec 1998)
aphasia, primary progressive A type of aphasia appearing gradually and gradually worsening without any major change in other cognitive functions. It is regarded by some authors as a syndrome which may be due to various degenerative diseases of the cerebral cortex (notably alzheimer disease, owing to its frequency), while others see in it an autonomous disease related to a neuropathological process that is distinct from the main degenerative dementias. The principal clinical peculiarity of primary progressive aphasia is that it spares the patient's autonomy for a long time, but ultimately turns into global dementia.
(12 Dec 1998)
bovine progressive degenerative myeloencephalopathy A familiar myeloencephalopathy of brown Swiss cattle characterised by bilateral hindleg weakness and ataxia and deficient proprioceptive reflexes.
(05 Mar 2000)
rapidly progressive glomerulonephritis <nephrology> A relatively uncommon (affecting 1 out of 10,000 people) form of acute glomerulonephritis that results in damage within the glomerulus of the kidney. There is rapid loss of kidney function with the formation of crescents on microscopic analysis (kidney biopsy). This disorder may result in acute glomerulonephritis or nephrotic syndrome, but ultimately results in renal failure and end-stage renal disease.
Symptoms include smoky coloured urine (pyuria), decreased urine output, swelling and hypertension. Any conditions which can cause a vasculitis increase the risk of this disorder. Some examples include lupus, Goodpasture's syndrome, Henoch-Schonlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis, anti-glomerular basement membrane antibody disease, history for malignant tumours and exposure to hydrocarbon solvents.
(27 Sep 1997)
chronic progressive chorea A progressive disorder usually beginning in young to middle age, consisting of a triad of choreoathetosis, dementia, and autosomal dominant inheritance with complete penetrance. Bilateral marked wasting of the putamen and the head of the caudate nucleus is characteristic.
Synonym: chronic progressive chorea, degenerative chorea, hereditary chorea, Huntington's disease.
(05 Mar 2000)
chronic progressive external ophthalmoplegia A specific type of slowly worsening weakness of the ocular muscles, usually associated with a pigmentary retinopathy.
See: Kearns-Sayre syndrome, oculopharyngeal dystrophy.
Synonym: ocular myopathy.
(05 Mar 2000)
chronic progressive syphilitic meningoencephalitis Syphilitic infection manifested as dementia (often with delusional features), dysarthria, seizures, myoclonic jerks, action tremor, impaired walking and standing, pupillary abnormalities, and abnormal CSF findings.
Synonym: chronic progressive syphilitic meningoencephalitis.
(05 Mar 2000)
pneumonia, progressive interstitial, of sheep Chronic respiratory disease caused by the visna-maedi virus. It was formerly believed to be identical with jaagsiekte (pulmonary adenomatosis, ovine) but is now recognised as a separate entity.
(12 Dec 1998)
primary progressive cerebellar degeneration A familial ataxic condition related to cerebellar degeneration.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á